Search

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

… Wednesday, July 22, 2020 The July 22 MSK Science Spotlight features Luis Diaz, MD , Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.” An accomplished physician, pioneering researcher, and leader in the field

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

… Wednesday, March 8, 2023 You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

… Monday, October 8, 2012 Summary Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells. For the first time, a team of Memorial Sloan Kettering investigators has synthesized erythropoietin (also known as EPO), the hormone

Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer.

… Saturday, December 8, 2012 Summary Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer. President Barack Obama announced on December 6 his intent to appoint Memorial Sloan

Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer care.

… Tuesday, August 4, 2015 Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer

Dana Pe’er, PhD, computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today.

… Thursday, September 23, 2021 Dana Pe’er, PhD , computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today. The elite group of scientists,

An enzyme that contributes to plaque formation in the brain also serves as a first line of defense against bacteria and viruses, suggesting a link between the two.

… Wednesday, September 2, 2020 Summary Scientists at the Sloan Kettering Institute have discovered a direct link between the immune response to viruses and bacteria and the development of plaques in the brain that characterize Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative condition that

Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it.

… Friday, July 11, 2014 Summary Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it. The word “transformation” perfectly characterizes and captures the past year at Memorial Sloan Kettering. Indeed, it’s the word we

Cancer often leaves those it touches consumed with a feeling of hopelessness. But sometimes that feeling can motivate clinicians, patients, and supporters alike to turn soul-crushing moments into positive change.

… Thursday, January 27, 2022 Cancer often leaves those it touches consumed with a feeling of hopelessness. But sometimes that feeling can motivate clinicians, patients, and supporters alike to turn soul-crushing moments into positive change. Dave Linn and Jennifer Goodman Linn used their experience with

An international phase 3 clinical trial has shown that adding a targeted therapy to a standard combination for stage 4 kidney cancer is more effective than giving the standard treatment alone, although the new combination has significant side effects.

… Wednesday, May 10, 2023 Michael Szczerbienski had always been blessed with good health, so the day he found blood in his urine , he was quite alarmed. His doctor sent him for a CT scan , which revealed a tumor on his left kidney. Michael, whose kidney cancer was already advanced, went to Memorial Sloan